Zinc Supplementation in Cholera Patients

Learn more about:
Related Clinical Trial
Preventative Intervention for Cholera for 7 Days Impact Study of Cholera Vaccination in Endemic Areas – Clinical Surveillance Water, Sanitation, and Hygiene Mobile Health Messages as an Innovative Tool to Facilitate Behavior Change Non-Inferiority, Safety and Lot-to-Lot Consistency of Oral Cholera Vaccine-Simplified Compared to Shanchol™ in Nepalese Safety and Immunogenicity of Peru-15 Vaccine When Given With Measles Vaccine in Healthy Indian and Bangladeshi Infants Safety and Immunogenicity of Single Dose Choleragarde® in HIV-Seropositive Adults PXVX0200 (CVD103-HgR) vs Shanchol in Mali Cholera-Hospital-Based-Intervention-for-7-days A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Adults Follow-up of Pregnant Women After a Mass Vaccination of Oral Cholera Vaccine (ShancholTM) in Nsanje Malawi Single Dose Azithromycin in the Treatment of Adult Cholera Safety and Immunogenicity of a New Formulation of Euvichol® Cholera Anti-Secretory Treatment Trial PK Study of iOWH032 in Adult Male/Female Healthy Volunteers & Adult Males With Cholera Single Dose Ciprofloxacin in the Treatment of Childhood Cholera:Randomized Controlled Clinical Trial Efficacy of Benefiber-Added, Reduced-Osmolarity WHO-ORS in the Treatment of Cholera in Adults Safety and Immunogenicity of Locally Manufactured New (HL-OCV) Oral Cholera Vaccine Zinc Supplementation in Cholera Patients Immunologic Responses to a Live Attenuated Oral Cholera Vaccine Pilot Introduction of Oral Cholera Vaccine in Orissa, India Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200 Immunity to Human Cholera in Bangladesh Ciprofloxacin Multiple Dose for Adult Cholera Effect of Probiotic on Immunogenicity of Oral Cholera Vaccine Effectiveness of a Bivalent Killed Whole Cell Based Oral Cholera Vaccine Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera Impact Evaluation of Urban Water Supply Improvements on Cholera and Other Diarrhoeal Diseases in Uvira, Democratic Republic of Congo Protective Immunity to Human Cholera in Bangladesh Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine Oral Cholera Vaccine Delivery in Rural Bangladesh Study of Alternative Vaccination Schedule of Oral Cholera Vaccine Mass Oral Cholera Vaccination in Zanzibar Cholera Vaccine Investment Strategy in Bangladesh Immunogenicity of One Versus Two Doses of Killed Oral Cholera Vaccine Bridging Study for Killed Oral Cholera Vaccine in Ethiopia Safety and Immunogenicity of Locally Manufactured Oral Cholera Vaccine Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in Dominican Republic Introduction of Cholera Vaccine in Bangladesh Evaluation of a Pilot Program to Introduce Cholera Vaccine in Haiti as Part of Global Cholera Control Efforts Single Dose Oral Cholera Vaccine Study in Dhaka, Bangladesh Evaluation of a Boosting Regimen With Oral Cholera Vaccine Single Dose Azithromycin to Prevent Cholera in Children Safety and Immunogenicity of Oral Cholera Vaccine in Kolkata A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in the Philippines Randomized Controlled Trial of Killed Oral Cholera Vaccine in Kolkata

Brief Title

Zinc Supplementation in Cholera Patients

Official Title

Clinical Trial of Zinc Supplementation in Cholera Patients

Brief Summary

      Cholera is one of the leading causes of morbidity and mortality among children and adult in
      developing countries. We will evaluate the effect of supplementation of zinc on reduction of
      duration and severity of cholera. Since cholera is primarily a disease of older children and
      adults, we intend to study the effects of zinc supplementation among children of 3 to 14
      years of age, whose initial stool weight will be >4ml/kg/hour in 1st 6 hours and dark field
      examination is positive. 90 subjects in each group hospitalized with cholera with diarrhea
      for less than 24 hours will be selected. After inclusion in the study, informed consent will
      be obtained from guardian explaining the full procedure in the hospital. The subjects will be
      randomized to receive either zinc or placebo until diarrhea resolves. History of illness and
      baseline information will be collected in the hospital through interview, which may take
      duration of 10 minutes.After 6 hours of initial rehydration, fluid balance study will be
      carried out on all subjects until diarrhea resolves. 1 ml (1/4 teaspoonful) of blood sample
      will be taken to assess serum zinc level on admission after initial hydration and will be
      repeated on the day of recovery. This procedure carries a small risk of infection if not done
      under sanitary conditions; however, we will maintain proper sanitation, so there is no risk
      in the procedures. There is no potential risk in this study.20mg elemental Zinc will be given
      daily in 2 divided doses till cholera resolves. Both groups will receive syrup or tablet
      Erythromycin 50mg/kg/24 in 4 divided doses for 3 days. Oral rehydration solution/intravenous
      acetate fluid will be used for rehydration. Daily body weight will be taken and stool will be
      sent for C/S until the day of recovery or 5 days. Zinc loss in stool will be seen in 20% of
      random stool samples. Information obtained from history and the laboratory investigations of
      subject will be kept strictly confidential and no one other than the investigators of this
      study and the Ethics Committee of this Centre will/ has access to the information. The study
      will benefit the patients as study physician will do close observation, examination and will
      take care frequently, as research staff will monitor systematic progress and take necessary
      action. Study micronutrient (zinc) is shown to have benefit in children in acute diarrhea. If
      the results of the study is positive, it will benefit the patients in their treatment during
      this study and thereafter. The data will be analyzed for clinical effects of zinc on
      diarrhea.The study will help to improve the treatment strategy of cholera in children. The
      study will use hospital records, which will be returned after completion of the study. Stool,
      urine and 1 ml (1/4 teaspoonful) of venous blood will be taken to assess serum zinc level.
    

Detailed Description

      Study design:

      A double blind randomized clinical trial using zinc and placebo.

      Randomization:

      Patients will be randomized to one of two groups, A or B. Block randomization will be done
      using block length of 6. Group A will receive Zinc+ Erythromycin and Group B: will receive
      Placebo+Erythromycin

      Dose of Erythromycin

      Syrup/tab Erythromycin 50mg/kg/24 hours in 4 divided doses for 3 days.

      Dose of zinc:

      Zinc acetate will be given at 10mg twice daily (10mgx2=20mg elemental zinc) until cholera
      resolves (the time of passage of last unformed stool or first formed stool followed by 24
      hours without any diarrheal stool).

      Composition of the syrup:

      For both groups, the bulk of the base syrup will be consist of the same chemicals; in
      addition to this, group A will have the treatment substance (i.e. elemental zinc 20 mg/day)

      Syrup A: Quantity per 5 ml

      Zinc Acetate 10 mg elemental zinc

      Syrup B: Base substance

      Base Substance:

      Ascorbic acid 30 mg Glycerin USP 1.2 ml Propylene glycol USP 0.75 ml Sorbitol 70% BP 2.0 ml
      Methyl Paraben USFN 3.5 mg Polysorate-80 50 mg (Tween -80) BPC Lemon oil PH grade 0.0125 ml
      Caramel Brown colour 1 mg Purified water 0.75 ml

      Clinical procedure in the hospital:

      Patients who meet the selection criteria will be observed for initial six hours, while their
      urine and stool specimen will be collected separately. Patient whose initial stool-output
      >4ml/kg/hour during this period and dark field examination of stool is positive will be
      enrolled in the study. Patients will be kept in study ward. After complete hydration,
      patients will be randomised in blocks of 6 to one of two groups A and B. Group A will receive
      syrup zinc and group B will receive placebo till cholera resolves. Both the groups will
      receive the identical bottles containing syrup with same flavor and only single unique serial
      number will be written on the bottles. The number will indicate an exact subject of study.
      Both the groups will receive Syrup/Tab Erythromycin. 1ml blood will be collected for serum
      zinc on admission after complete dehydration and this test will be repeated at the time of
      discharge. Stool culture and sensitivity (C/S) will be sent daily until the day of recovery
      or 5 days. Balance will be performed on all the patients till cholera resolves. If any
      complication develops after enrollment, study will be discontinued and patient will be
      treated accordingly.

      Assessment of dehydration:

      To reduce observational variation, especially regarding the assessment of dehydration, a
      standardized form is developed for the assessment of dehydration.

      CONDITION* (1=normal, 2=irritable/lessactive, 3=lethargic/comatose) MUCOSA (1=normal, 2=dry)

      EYES (1=normal, 2=sunken) THIRST* (1=normal, 2=thirsty, 3=unable to drink) SKIN TURGOR*
      (1=normal, 2=reduced) PULSE* (1=normal, 3=feeble/absent)

      DEHYDRATION STATUS:

        1. no sign of dehydration

        2. some dehydration (two signs coded 2 with at least one key sign*)

        3. severe dehydration (some dehydration, plus one key sign* coded 3)

      (* This method was recently validated by a group of international experts in oral rehydration
      therapy who were invited to ICDDR, B and is currently being used in a large WHO sponsored
      multi-centre trial for the evaluation of low osmolarity ORS. The investigators have been
      trained in this method).

      Rehydration phase:

      All the patients recruited in this study, will have either, some dehydration or severe
      dehydration. Therefore, before being randomized into study, during initial 6 hours all the
      patients will be rehydrated either by ORS or intravenous fluid. Patients with signs of some
      dehydration will be rehydrated by ORS and patients with severe dehydration will be rehydrated
      intravenously as described below. The following IV fluids will be used:

      Sodium Potassium Chloride Acetate Dhaka Solution (mmol/L) (mmol/L) (mmol/L) (mmol/L) 133 13
      98 48 Rate of administration will be 100 ml/kg over 4 hours, plus volume-for-volume
      replacement for ongoing losses hourly.

      If, at the end of four hours:

        1. The patient is fully rehydrated, he/she will be randomized to one of the treatment
           groups;

        2. Some dehydration persist, IV infusion will continue at the rate of 50 ml /kg over 2
           hours, plus replacement volume for volume of ongoing losses;

        3. Severe dehydration persists, IV infusion will continue for an additional 2 hours at the
           rate of 100 ml/kg, plus replacement of ongoing losses. This is very unusual, however,
           occurring only in very few patients who pass large watery stools frequently.

      If at the end of six hours, the patient is fully rehydrated patient will be randomized to one
      of the treatment group. If signs of dehydration persist after 6 hours, the patient will be
      excluded from study. All intake and output during this initial rehydration phase will be
      recorded.

      Maintenance phase:

      After completion of rehydration, subjects will be randomized to one of the two groups Group A
      and Group B. Group A will be given zinc acetate and group B will be given placebo. The
      supplementation of zinc or placebo will be continued till diarrhea resolves. Ongoing stool
      losses will be replaced with equal volume of Rice-ORS.

      Dietary management:

      Standardize hospital diet will be given to all patients which includes milk suji, rice,
      vegetable, daal, bread banana and chicken or fish.

      Intake and output measurement:

      All oral and intravenous fluid will be measured and recorded until cholera resolves. Stool
      weight will be measured separately from urine every 8 hours until cholera resolves. Urine
      will be separated and measured 8 hourly, weight of vomitus will also be taken 8 hourly. Daily
      clinical examination will be done by the investigators and study physician with observation
      on stool consistency and character.

      Clinical recovery:

      Clinical recovery will be defined as the time of passage of last unformed stool or first
      formed stool followed by 24 hours without any diarrheal stool.

      Sample size calculation:

      We assume that zinc will reduce 20% of mean duration of illness compared to erythromycin
      group18 at 90% power and 5% level of confidence. Therefore the sample size will be:

      n=2 (SD)2 aß/(D)2 n=2 (5)2 10.5/(2.6)2 n=77.66=78 per treatment group So the total number of
      samples will be 78 x 2 =156. Considering 15% drop out the total number of samples will be
      156+24=180

      Assessment of weight gain:

      Weight will be taken on admission and daily until cholera resolves.

      Laboratory tests:

        1. Microscopic examination

           1. Dark field examination will be done on stool samples on admission.

        2. Microbiological assays:

           1 Daily stool C/S will be done till cholera resolves or 5 days.

        3. Micronutrient assay:

             1. Serum zinc level will be obtained on day 1 and on the day of recovery

             2. Randomly zinc loss in cholera will be seen in 20% samples.
    

Study Phase

Phase 3

Study Type

Interventional


Primary Outcome

Reduction in duration of diarrhoea

Secondary Outcome

 Serum Zinc status

Condition

Cholera

Intervention

Zinc


Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug


Start Date

November 2000

Completion Date

July 2002


Eligibility Criteria

        Inclusion Criteria:

          -  Children aged between 3-14 years hospitalized at ICDDR, B presenting with cholera
             within 24 hours of onset.

          -  Stool output more than 4ml/kg/hour within the first 6 hours of observation period.

          -  Positive dark field examination

        Exclusion Criteria:

          -  Unable to rehydrate within 6 hours

          -  Negative dark field examination

          -  Systemic illness requiring immediate administration of antibiotics.

          -  Received antibiotics in the 24 hours prior to hospitalization

          -  Patients presenting with bloody mucoid diarrhea

          -  Unconscious or medical emergencies
      

Gender

All

Ages

3 Years - 14 Years

Accepts Healthy Volunteers

No

Contacts

Swapan K Roy, MBBS,MSc,Phd, , 

Location Countries

Bangladesh

Location Countries

Bangladesh

Administrative Informations


NCT ID

NCT00226616

Organization ID

99-022



Study Sponsor

International Centre for Diarrhoeal Disease Research, Bangladesh

Collaborators

 Thrasher Research Fund

Study Sponsor

Swapan K Roy, MBBS,MSc,Phd, Principal Investigator, International Centre for Diarrhoeal Disease Research, Bangladesh


Verification Date

September 2005